A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes

NCT00675857 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Metabolic Syndrome X

Interventions

DRUG: NC-503 (eprodisate disodium)
OTHER: placebo

Sponsor

Bellus Health Inc. - a GSK company